Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Return on Capital Employed: 2013-2025

Historic Return on Capital Employed for Agios Pharmaceuticals (AGIO) over the last 12 years, with Sep 2025 value amounting to -0.35%.

  • Agios Pharmaceuticals' Return on Capital Employed changed negligibly% to -0.35% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.35%, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of -0.35% for FY2024, which is 3.00% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Return on Capital Employed stood at -0.35% for Q3 2025, which was down 9.84% from -0.32% recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Return on Capital Employed ranged from a high of -0.17% in Q2 2021 and a low of -0.54% during Q2 2024.
  • For the 3-year period, Agios Pharmaceuticals' Return on Capital Employed averaged around -0.37%, with its median value being -0.35% (2025).
  • Its Return on Capital Employed has fluctuated over the past 5 years, first rose by 25bps in 2021, then declined by 19bps in 2024.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Return on Capital Employed stood at -0.26% in 2021, then decreased by 7bps to -0.34% in 2022, then declined by 9bps to -0.43% in 2023, then rose by 17bps to -0.26% in 2024, then remained steady at -0.35% in 2025.
  • Its Return on Capital Employed stands at -0.35% for Q3 2025, versus -0.32% for Q2 2025 and -0.28% for Q1 2025.